Shanghai Zejing Pharmaceutical Technology Co., Ltd.

Primary objective: To evaluate the effects of itraconazole and rifampicin on the pharmacokinetics (PK) of Jaktinib hydrochloride and its major metabolites ZG0244 and ZG0245 in healthy subjects. Secondary objective: To evaluate the effects of itraconazole and rifampicin on the safety of Jaktinib hydrochloride in healthy subjects.

Phase 1: Dose escalation Primary objective: To evaluate the safety and tolerability of Jaktinib hydrochloride tablets combined with azacitidine in patients with myelodysplastic syndrome with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasms with myelofibrosis. To determine the recommended dose (RP2D) for Phase II. Secondary objective: To evaluate the efficacy of Jaktinib hydrochloride tablets combined with azacitidine in patients with MDS and MF or MDS/MPN with MF. Exploratory objective: To explore the correlation between MDS or MDS/MPN-related biomarkers and efficacy. Phase 2: Dose expansion Primary objective: To evaluate the efficacy of Jaktinib hydrochloride tablets combined with azacitidine in patients with MDS and MF or MDS/MPN with MF. Secondary objective: To evaluate the safety of Jaktinib hydrochloride tablets combined with azacitidine in patients with MDS and MF or MDS/MPN with MF. Exploratory objective: To explore the correlation between MDS or MDS/MPN-related biomarkers and efficacy.

PART 1: (1) Explore the safety of ZG005 combined with gecaxitinib hydrochloride tablets in patients with relapsed or refractory lymphoma; (2) Confirm the recommended Phase II dosing regimen for relapsed or refractory lymphoma. PART 2: Evaluate the effectiveness of ZG005 combined with gecaxitinib hydrochloride tablets in relapsed or refractory lymphoma.